Colonic cancer: incidence, pattern &role of radical surgery in stage 11AND 111,in al nassiryia


  • alaa jamel hasin (C.A.B.S), medical college, the-qar university


Ca. colon, radical resection, Stage 11, 111


Background: Invasive colorectal cancer is a preventable disease. Early detection through widely applied screening programs is the most important factor in the recent decline of colorectal cancer in developed countries .Full implementation of the screening guideline scan decrease mortality rate from colorectal cancer in the United States by an estimated additional 50%; even greater reductions are estimated for countries where screening tests may not be widely available at present. New and more comprehensive screening strategies are also needed.[1] Fundamental advances in understanding the biology and genetics of colorectal cancer are taking place. This knowledge is slowly making its way into the clinic and being employed to better stratify individual risks of developing colorectal cancer, discover better screening methodologies, allow for better prognostication, and improve one’s ability to predict benefit from new anticancer therapies.[2] In the past 10 years, an unprecedented advance in systemic therapy for colorectal cancer has dramatically improved outcome for patients with metastatic disease. Until the mid-1990s, the only approved agent for colorectal cancer was 5-fluorouracil. New agents that became available in the past 10 years include cytotoxic agents such as irinotecan and oxaliplatin,oral fluoropyrimidines (capecitabine and tegafur), and biologic agents such as bevacizumab, cetuximab, and panitumumab.Though surgery remains the definitive treatment modality, these new agents will likely translate into improved cure rates for patients with early stage disease (stage II and III) and prolonged survival for those with stage IV disease. Further advances are likely to come from the development of new targeted agents and integration of those agents with other modalities such as surgery, radiation therapy, and liver-directed therapies.[3] this study was done in Al Nassyria in Al Hussein teaching hospital through 2 years from April 2008 to March 2010  with 3 years fallow up on 32 patients complaining from stage 11 and stage 111  colonic cancer, 10 of them they arrived to the hospital as an emergency cases with intestinal obstruction or uncontrolled bleeding per rectum and 22 cases as an elective cases who presented from either sub acute intestinal obstruction, chronic loss of weight, chronic loss of appetite abdominal mass and or intermittent bleeding per rectum , ages of patients range between 30 to 80 years.18 patients males and 14 patients were females. Aim is To make screening for  stage 11& 111 colonic cancer admitted to our unit and role of radical surgery in emergency cases comparing with radical surgery in elective surgery . Ca. of rectum was excluded from the study. We get 84%(27 patients) above 50 years, males were more,18 patients, annular type were the commonest type (50%). , about histopathological study 18 patients (56.25%)were moderately differentiation ,9 patients (28.1%)poorly differentiation and 5 patients (15.6%) were well differentiation. There were no significant differences of radical surgery in elective and emergency presented cases in recurrence and post operative complications.


[Guideline] Desch CE, Benson AB 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. Nov 20 2005;23(33):8512-9. [Medline]

Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?.Am J Gastroenterol. Nov 2011;106(11):1911-21; quiz 1922. [Medline].

[Best Evidence] Jacobs ET, Ahnen DJ, Ashbeck EL, Baron JA, Greenberg ER, Lance P, et al. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol. Mar 15 2009;169(6):657-66. [Medline].

Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. Apr 27 2011;305(16):1685-94. [Medline]. [Full Text].

Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management. J Natl Cancer Inst. Apr 20 2011;103(8):689-97. [Medline].

Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer. May 2 2007;7:72. [Medline].

[Best Evidence] Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet. Dec 15 2007;370(9604):2020-9. [Medline].

Saltz LB, Kelsen DP. Adjuvant treatment of colorectal cancer. Annu Rev Med. 1997;48:191-202. [Medline].

Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. Jul 17 2003;349(3):247-57. [Medline].

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. Feb 20 2011;29(6):610-8. [Medline].

Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. Aug 1 2003;21(15):2912-9. [Medline].

[Best Evidence] Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. Jan 10 2010;28(2):264-71. [Medline].

Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. Jan 15 2004;22(2):229-37. [Medline].

[Best Evidence] Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. Dec 20 2008;26(36):5910-7. [Medline].

Sehgal R, Lembersky BC, Rajasenan KK, et al. A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer. Clin Colorectal Cancer. Jun 2011;10(2):117-20. [Medline].

[Best Evidence] Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. Jun 10 2009;27(17):2848-54. [Medline].

Brouquet A, Overman MJ, Kopetz S, et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?.Cancer. Oct 1 2011; 117(19):4484-92. [Medline]. [Full Text].

Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomized factorial trial. Lancet. May 21 2011;377(9779):1749-59. [Medline].

Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. Jan 1 2004;22(1):23-30. [Medline].